NCT07543172 2026-04-21
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Not yet recruiting
Clinical Trials
8 trialsNCT07288034 2026-04-15
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT03994796 2026-04-13
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT06248606 2026-04-08
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07415031 2026-04-08
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Not yet recruiting
NCT05853575 2026-03-27
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Phase 2 Active not recruiting
NCT05673187 2026-01-21
ADEPPT
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT05472623 2025-09-15
Neo-Kan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn